Amneal Pharmaceuticals, Inc. AMRX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $78M+217% | $49.57M+339% | $18.13M+54.2% | $35.61M+112% | $24.62M+130% | ||
| $8.82M+21.5% | $8.2M+13.8% | $8.22M+15.6% | $8.27M+23.1% | $7.26M+8.0% | ||
| $3.89M-42.9% | $3.72M-45.5% | $5.03M-37.3% | $6.88M-7.7% | $6.81M+0.1% | ||
| -$44.01M-108% | $10.34M-63.9% | $77.61M— | $53.76M-46.6% | -$21.15M-138% | ||
| $54.96M+314% | $20.18M-61.2% | $30.81M-28.5% | $22.78M-2.0% | $13.26M+8.7% | ||
| -$124.58M-10.6% | $18.58M-72.0% | $69.75M+48.9% | $45.62M-23.8% | -$112.63M-281% | ||
| $13.4M+2,512% | $0— | $10.16M— | $9.5M— | $513K-95.6% | ||
| -$1.49M-13.2% | -$1.16M+53.8% | -$1.32M-193% | -$941K-134% | -$1.31M+2.7% | ||
| -$3.51M— | —— | -$31.37M— | —— | $0— | ||
| -$26.74M-461% | $130.32M+10.4% | $118.45M-16.5% | $83.82M+111% | $7.41M+268% | ||
| $8.18M-37.9% | $21.77M+43.7% | $12.3M-27.4% | $22.83M+115% | $13.16M+43.1% | ||
| $7.85M+86.9% | $3M+400% | $7.41M+106% | $900K+20.0% | $4.2M-56.7% | ||
| $0-100% | —— | —— | $855K— | $524K— | ||
| -$21.71M-22.0% | -$45.45M-183% | -$22.46M-8.5% | -$26.55M-311% | -$17.8M+9.9% | ||
| $134.67M— | $2.48B+5,260% | $0— | $218M— | $0-100% | ||
| $38K-44.9% | $553K+266% | $653K+5.8% | $685K+91.3% | $69K+146% | ||
| $44.31M+105% | $321K-17.1% | $129K-33.5% | $189K+18.9% | $21.64M+200% | ||
| $1.98M— | —— | $73.23M— | $1.75M— | $0— | ||
| -$59.06M-50.8% | -$10.12M+83.5% | —— | -$41.69M-18.8% | -$39.17M-69.1% | ||
| -$1.02M-118% | -$209K+71.8% | -$694K— | -$307K-204% | -$470K-185% | ||
| -$108.53M-117% | $74.53M+86.0% | $154.74M+439% | $15.28M+866% | -$50.03M-5.3% | ||
| $56.45M+0.2% | $41.4M-31.7% | $43.8M-34.0% | $56.32M-21.8% | $56.32M-12.7% | ||
| $2.45M+168% | $3.75M-39.1% | $5.01M— | $16.18M+187% | -$3.61M-179% | ||
| $3.89M-42.9% | $3.72M-45.5% | $5.03M-37.3% | $6.88M-7.7% | $6.81M+0.1% | ||
| $43.19M-28.2% | $49.23M-25.6% | $54.07M-8.3% | $60.11M+8.2% | $60.16M+8.3% | ||
| -$8.22M-328% | —— | —— | $8.22M+1,544% | $3.6M+338% | ||
| $56K+2,700% | —— | —— | $1.11M+1,576% | $2K-99.6% | ||
| -$41.1M-3,557% | —— | —— | $6.42M+55.6% | -$1.12M-120% | ||
| $13.4M+2,512% | $0— | $10.16M— | $9.5M— | $513K-95.6% | ||
| -$2.88M-145% | -$2.94M-145% | —— | —— | $6.44M— | ||
| $13.35M-43.6% | $26.64M-19.2% | $20.89M-5.5% | $14.76M-20.5% | $23.67M+3.3% | ||
| -$1.49M-13.2% | -$1.16M+53.8% | -$1.32M-193% | -$941K-134% | -$1.31M+2.7% | ||
| $7.85M+86.9% | $3M+400% | $7.41M+106% | $900K+20.0% | $4.2M-56.7% | ||
| $5.69M+492% | $21.4M+193% | $2.75M+1,548% | $3.67M+4,608% | $960K+11.4% | ||
| $0-100% | —— | —— | $855K— | $524K— | ||
| —— | $523.5K— | $523.5K— | $523.5K— | $523.5K— | ||
| —— | $18.74M+105,496% | $18.74M+105,496% | $18.74M+105,496% | $18.74M+105,496% | ||
| $510K— | $795K— | —— | —— | $0— | ||
| $134.67M— | —— | —— | —— | $0— | ||
| $140.84M-40.2% | -$5.62B-1,643% | $2.55B+4,586% | $15.55M+0.3% | $235.53M+272% | ||
| $7.15M+10,410% | —— | $13.87M+149% | $24.89M— | $68K— | ||
| $1.35M-20.6% | —— | —— | —— | $1.7M— | ||
| $2.45M+168% | $3.75M-39.1% | $5.01M— | $16.18M+187% | -$3.61M-179% | ||
| $0-100% | —— | —— | —— | $4.81M+27.2% | ||
| -$34.92M-507% | $108.54M+5.5% | $106.15M-15.0% | $60.99M+110% | -$5.75M+57.7% | ||
| -$34.92M-507% | $108.54M+5.5% | $106.15M-15.0% | $60.99M+110% | -$5.75M+57.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Amneal Pharmaceuticals, Inc. generate?
- Amneal Pharmaceuticals, Inc. (AMRX) generated $305.8M in operating cash flow over the trailing twelve months.
- What is Amneal Pharmaceuticals, Inc.'s free cash flow?
- After $65.1M of capital expenditures, Amneal Pharmaceuticals, Inc.'s free cash flow was $240.8M over the trailing twelve months, down 4.1% year over year.
- Where does Amneal Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Amneal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
